{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T19:19:39Z","timestamp":1770837579144,"version":"3.50.1"},"reference-count":33,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T00:00:00Z","timestamp":1632873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Discipline innovation and development plan of Tangdu Hospital-major clinical research projects","award":["2021LCYJ002"],"award-info":[{"award-number":["2021LCYJ002"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>In this study, we report the safety of coronavirus disease 2019 (COVID-19) vaccine in patients with myasthenia gravis (MG). Patients who were vaccinated against COVID-19 were included. Demographics, clinical characteristics, medications, and vaccination information were collected. The main observation outcome is the worsening of MG symptoms within 4 weeks following COVID-19 vaccination. A total of 22 patients with MG vaccinated for COVID-19 were included. Ten (45.5%) patients had ocular MG (OMG), and 12 (55.5%) patients had generalized MG (GMG). Six (27.3%) patients were female, and the mean (SD) onset age was 45.4 (11.8) years. Nineteen (86.4%) patients were seropositive for acetylcholine receptors (AChR) antibody. Seven (31.8%) patients underwent thymectomy, and four of them confirmed thymoma pathologically. Twenty-one patients were administrated with inactivated vaccines, and the remaining one was administrated with recombinant subunit vaccine. Twenty (90.9%) patients did not present MG symptom worsening within 4 weeks of COVID-19 vaccination, and two (9.1%) patients reported slight symptom worsening but resolved quickly within a few days. Our findings suggest inactivated COVID-19 vaccines might be safe in MG patients with Myasthenia Gravis Foundation of America (MGFA) classification I to II, supporting the recommendation to promote vaccination for MG patients during the still expanding COVID-19 pandemic.<\/jats:p>","DOI":"10.3390\/vaccines9101112","type":"journal-article","created":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T01:59:47Z","timestamp":1633917587000},"page":"1112","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["COVID-19 Vaccination in Patients with Myasthenia Gravis: A Single-Center Case Series"],"prefix":"10.3390","volume":"9","author":[{"given":"Zhe","family":"Ruan","sequence":"first","affiliation":[{"name":"Department of Neurology, Tangdu Hospital, The Fourth Military Medical University, Xi\u2019an 710038, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonglan","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tangdu Hospital, The Fourth Military Medical University, Xi\u2019an 710038, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunhong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tangdu Hospital, The Fourth Military Medical University, Xi\u2019an 710038, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tangdu Hospital, The Fourth Military Medical University, Xi\u2019an 710038, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tangdu Hospital, The Fourth Military Medical University, Xi\u2019an 710038, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuyi","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tangdu Hospital, The Fourth Military Medical University, Xi\u2019an 710038, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tangdu Hospital, The Fourth Military Medical University, Xi\u2019an 710038, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"15530","DOI":"10.1073\/pnas.2007658117","article-title":"Economic and social consequences of human mobility restrictions under COVID-19","volume":"117","author":"Bonaccorsi","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/jama.2020.16349","article-title":"Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial","volume":"324","author":"Spinner","year":"2020","journal-title":"JAMA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"WHO Solidarity Trial Consortium (2021). Repurposed Antiviral Drugs for COVID-19\u2014Interim WHO Solidarity Trial Results. N. Engl. J. Med., 384, 497\u2013511.","DOI":"10.1056\/NEJMoa2023184"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1056\/NEJMoa2015301","article-title":"Remdesivir for 5 or 10 Days in Patients with Severe Covid-19","volume":"383","author":"Goldman","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","article-title":"Phase 1\u20132 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine","volume":"383","author":"Keech","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1001\/jama.2020.15543","article-title":"Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials","volume":"324","author":"Xia","year":"2020","journal-title":"JAMA"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ijid.2021.08.013","article-title":"Side Effects and Perceptions Following Sinopharm COVID-19 Vaccination","volume":"111","author":"Saeed","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/22221751.2021.1969291","article-title":"Efficacy of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: A test-negative case-control real-world study","volume":"10","author":"Li","year":"2021","journal-title":"Emerg. Microbes Infect."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2107715","article-title":"Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile","volume":"385","author":"Jara","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/mus.26689","article-title":"Factors associated with acute exacerbations of myasthenia gravis","volume":"60","author":"Gummi","year":"2019","journal-title":"Muscle Nerve"},{"key":"ref_15","first-page":"e2109","article-title":"Impact of Coronavirus Disease 2019 in a French Cohort of Myasthenia Gravis","volume":"96","author":"Mathis","year":"2021","journal-title":"Neurology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1111\/ene.14951","article-title":"Predictive factors for a severe course of COVID-19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival","volume":"28","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S1474-4422(20)30413-0","article-title":"COVID-19-associated risks and effects in myasthenia gravis (CARE-MG)","volume":"19","author":"Muppidi","year":"2020","journal-title":"Lancet Neurol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1475-2859-5-23","article-title":"Live bacterial vaccines\u2014A review and identification of potential hazards","volume":"5","author":"Detmer","year":"2006","journal-title":"Microb. Cell Fact."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s13167-017-0101-y","article-title":"Vaccination and autoimmune diseases: Is prevention of adverse health effects on the horizon?","volume":"8","author":"Poddighe","year":"2017","journal-title":"EPMA J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.vaccine.2019.01.007","article-title":"A prospective, double-blind, randomized, placebo-controlled study on the efficacy and safety of influenza vaccination in myasthenia gravis","volume":"37","author":"Strijbos","year":"2019","journal-title":"Vaccine"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1136\/annrheumdis-2012-201393","article-title":"Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: A case\u2013control study","volume":"72","author":"Mok","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.vaccine.2012.10.063","article-title":"Pandemic unadjuvanted influenza A (H1N1) vaccine in dermatomyositis and polymyositis: Immunogenicity independent of therapy and no harmful effect in disease","volume":"31","author":"Shinjo","year":"2012","journal-title":"Vaccine"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.vaccine.2013.01.057","article-title":"Short and long-term effects of pandemic unadjuvanted influenza A(H1N1)pdm09 vaccine on clinical manifestations and autoantibody profile in primary Sj\u00f6gren\u2019s syndrome","volume":"31","author":"Pasoto","year":"2013","journal-title":"Vaccine"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"577599","DOI":"10.1016\/j.jneuroim.2021.577599","article-title":"Safety and efficacy of COVID-19 vaccines in multiple sclerosis patients","volume":"356","author":"Kelly","year":"2021","journal-title":"J. Neuroimmunol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Watad, A., De Marco, G., Mahajna, H., Druyan, A., Eltity, M., Hijazi, N., Haddad, A., Elias, M., Zisman, D., and Naffaa, M. (2021). Immune-Mediated Disease Flares or New-Onset Disease in 27 Subjects Following mRNA\/DNA SARS-CoV-2 Vaccination. Vaccines, 9.","DOI":"10.3390\/vaccines9050435"},{"key":"ref_26","first-page":"e15581","article-title":"A Case of COVID-19 Vaccine Causing a Myasthenia Gravis Crisis","volume":"13","author":"Tagliaferri","year":"2021","journal-title":"Cureus"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3988\/jcn.2017.13.4.325","article-title":"The Impacts of Influenza Infection and Vaccination on Exacerbation of Myasthenia Gravis","volume":"13","author":"Seok","year":"2017","journal-title":"J. Clin. Neurol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"6290","DOI":"10.1016\/j.vaccine.2017.09.078","article-title":"A prospective, placebo controlled study on the humoral immune response to and safety of tetanus revaccination in myasthenia gravis","volume":"35","author":"Strijbos","year":"2017","journal-title":"Vaccine"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1002\/mus.21440","article-title":"Safety of influenza vaccination in patients with myasthenia gravis: A population-based study","volume":"40","author":"Zinman","year":"2009","journal-title":"Muscle Nerve"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/mus.22077","article-title":"Safety of influenza and H1N1 vaccinations in patients with myasthenia gravis, and patient compliance","volume":"43","author":"Auriel","year":"2011","journal-title":"Muscle Nerve"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ebiom.2018.01.007","article-title":"Acetylcholine Receptor Antibody Titers and Clinical Course after Influenza Vaccination in Patients with Myasthenia Gravis: A Double-Blind Randomized Controlled Trial (ProPATIent-Trial)","volume":"28","author":"Tackenberg","year":"2018","journal-title":"EBioMedicine"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3899\/jrheum.170710","article-title":"A Systematic Review and Metaanalysis of Antirheumatic Drugs and Vaccine Immunogenicity in Rheumatoid Arthritis","volume":"45","author":"Subesinghe","year":"2018","journal-title":"J. Rheumatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/acr.22246","article-title":"Effect of Methotrexate, Anti-Tumor Necrosis Factor \u03b1, and Rituximab on the Immune Response to Influenza and Pneumococcal Vaccines in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis","volume":"66","author":"Hua","year":"2014","journal-title":"Arthritis Rheum."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/10\/1112\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:07:34Z","timestamp":1760166454000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/10\/1112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,29]]},"references-count":33,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["vaccines9101112"],"URL":"https:\/\/doi.org\/10.3390\/vaccines9101112","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,29]]}}}